# A Randomized, Double-blind, Active Control, Parallel Group, Titration, Multicenter Study to Evaluate the Efficacy and Safety of Fimasartan

> **NCT02620306** · PHASE3 · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 351 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** Fimsartan 60mg~120mg
- **DRUG:** Fimsartan 60mg~120mg
- **DRUG:** Losartan 50mg~100mg
- **DRUG:** Losartan 50mg~100mg

## Key facts

- **NCT ID:** NCT02620306
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-11
- **Primary completion:** 2019-12-23
- **Final completion:** 2022-05-11
- **Target enrollment:** 351 (ACTUAL)
- **Last updated:** 2022-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02620306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02620306, "A Randomized, Double-blind, Active Control, Parallel Group, Titration, Multicenter Study to Evaluate the Efficacy and Safety of Fimasartan". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02620306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*